Selected research
Market Outlook & Growth Opportunities
Global Pet Tumor Screening Service Market Outlook and Growth Opportunities 2026
Market perspective
The global Pet Tumor Screening Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Pet Tumor Screening Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pet Tumor Screening Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pet Tumor Screening Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Pet Tumor Screening Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Pet Tumor Screening Service market include PetDx, CYTOGEN, BioChain, Small Door, ANGLE, BioChain Institute Inc., CANCAN DIAGNOSTICS., IDEXX Laboratories and Zoetis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Pet Tumor Screening Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pet Tumor Screening Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pet Tumor Screening Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pet Tumor Screening Service market.
Pet Tumor Screening Service Segment by Company
PetDx
CYTOGEN
BioChain
Small Door
ANGLE
BioChain Institute Inc.
CANCAN DIAGNOSTICS.
IDEXX Laboratories
Zoetis
Pet Tumor Screening Service Segment by Type
Cut Biopsy
Needle Biopsy
Pet Tumor Screening Service Segment by Application
Pet Hospital
Clinic
Scientific Research Institutions
Pet Tumor Screening Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pet Tumor Screening Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Pet Tumor Screening Service key companies, revenue, market share, and recent developments.
3. To split the Pet Tumor Screening Service breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Pet Tumor Screening Service market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pet Tumor Screening Service significant trends, drivers, influence factors in global and regions.
6. To analyze Pet Tumor Screening Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Tumor Screening Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pet Tumor Screening Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Tumor Screening Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pet Tumor Screening Service industry.
Chapter 3: Detailed analysis of Pet Tumor Screening Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Pet Tumor Screening Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Pet Tumor Screening Service in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Cut Biopsy
- Needle Biopsy
Applications
- Pet Hospital
- Clinic
- Scientific Research Institutions
Companies covered
- PetDx
- CYTOGEN
- BioChain
- Small Door
- ANGLE
- BioChain Institute Inc.
- CANCAN DIAGNOSTICS.
- IDEXX Laboratories
- Zoetis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pet Tumor Screening Service Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pet Tumor Screening Service Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pet Tumor Screening Service Market Dynamics
- 2.1 Pet Tumor Screening Service Industry Trends
- 2.2 Pet Tumor Screening Service Industry Drivers
- 2.3 Pet Tumor Screening Service Industry Opportunities and Challenges
- 2.4 Pet Tumor Screening Service Industry Restraints
3 Pet Tumor Screening Service Market by Company
- 3.1 Global Pet Tumor Screening Service Company Revenue Ranking in 2025
- 3.2 Global Pet Tumor Screening Service Revenue by Company (2021-2026)
- 3.3 Global Pet Tumor Screening Service Company Ranking (2024-2026)
- 3.4 Global Pet Tumor Screening Service Company Manufacturing Base and Headquarters
- 3.5 Global Pet Tumor Screening Service Company Product Type and Application
- 3.6 Global Pet Tumor Screening Service Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Pet Tumor Screening Service Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Pet Tumor Screening Service Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Pet Tumor Screening Service Market by Type
- 4.1 Pet Tumor Screening Service Type Introduction
- 4.1.1 Cut Biopsy
- 4.1.2 Needle Biopsy
- 4.2 Global Pet Tumor Screening Service Sales Value by Type
- 4.2.1 Global Pet Tumor Screening Service Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pet Tumor Screening Service Sales Value by Type (2021-2032)
- 4.2.3 Global Pet Tumor Screening Service Sales Value Share by Type (2021-2032)
5 Pet Tumor Screening Service Market by Application
- 5.1 Pet Tumor Screening Service Application Introduction
- 5.1.1 Pet Hospital
- 5.1.2 Clinic
- 5.1.3 Scientific Research Institutions
- 5.2 Global Pet Tumor Screening Service Sales Value by Application
- 5.2.1 Global Pet Tumor Screening Service Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pet Tumor Screening Service Sales Value by Application (2021-2032)
- 5.2.3 Global Pet Tumor Screening Service Sales Value Share by Application (2021-2032)
6 Pet Tumor Screening Service Regional Value Analysis
- 6.1 Global Pet Tumor Screening Service Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pet Tumor Screening Service Sales Value by Region (2021-2032)
- 6.2.1 Global Pet Tumor Screening Service Sales Value by Region: 2021-2026
- 6.2.2 Global Pet Tumor Screening Service Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pet Tumor Screening Service Sales Value (2021-2032)
- 6.3.2 North America Pet Tumor Screening Service Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Pet Tumor Screening Service Sales Value (2021-2032)
- 6.4.2 Europe Pet Tumor Screening Service Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Pet Tumor Screening Service Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Pet Tumor Screening Service Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Pet Tumor Screening Service Sales Value (2021-2032)
- 6.6.2 South America Pet Tumor Screening Service Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Pet Tumor Screening Service Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Pet Tumor Screening Service Sales Value Share by Country, 2025 VS 2032
7 Pet Tumor Screening Service Country-level Value Analysis
- 7.1 Global Pet Tumor Screening Service Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Pet Tumor Screening Service Sales Value by Country (2021-2032)
- 7.2.1 Global Pet Tumor Screening Service Sales Value by Country (2021-2026)
- 7.2.2 Global Pet Tumor Screening Service Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.7.2 France Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.14.2 China Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.17.2 India Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Pet Tumor Screening Service Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Pet Tumor Screening Service Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Pet Tumor Screening Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 PetDx
- 8.1.1 PetDx Company Information
- 8.1.2 PetDx Business Overview
- 8.1.3 PetDx Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.1.4 PetDx Pet Tumor Screening Service Product Portfolio
- 8.1.5 PetDx Recent Developments
- 8.2 CYTOGEN
- 8.2.1 CYTOGEN Company Information
- 8.2.2 CYTOGEN Business Overview
- 8.2.3 CYTOGEN Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.2.4 CYTOGEN Pet Tumor Screening Service Product Portfolio
- 8.2.5 CYTOGEN Recent Developments
- 8.3 BioChain
- 8.3.1 BioChain Company Information
- 8.3.2 BioChain Business Overview
- 8.3.3 BioChain Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.3.4 BioChain Pet Tumor Screening Service Product Portfolio
- 8.3.5 BioChain Recent Developments
- 8.4 Small Door
- 8.4.1 Small Door Company Information
- 8.4.2 Small Door Business Overview
- 8.4.3 Small Door Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.4.4 Small Door Pet Tumor Screening Service Product Portfolio
- 8.4.5 Small Door Recent Developments
- 8.5 ANGLE
- 8.5.1 ANGLE Company Information
- 8.5.2 ANGLE Business Overview
- 8.5.3 ANGLE Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.5.4 ANGLE Pet Tumor Screening Service Product Portfolio
- 8.5.5 ANGLE Recent Developments
- 8.6 BioChain Institute Inc.
- 8.6.1 BioChain Institute Inc. Company Information
- 8.6.2 BioChain Institute Inc. Business Overview
- 8.6.3 BioChain Institute Inc. Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.6.4 BioChain Institute Inc. Pet Tumor Screening Service Product Portfolio
- 8.6.5 BioChain Institute Inc. Recent Developments
- 8.7 CANCAN DIAGNOSTICS.
- 8.7.1 CANCAN DIAGNOSTICS. Company Information
- 8.7.2 CANCAN DIAGNOSTICS. Business Overview
- 8.7.3 CANCAN DIAGNOSTICS. Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.7.4 CANCAN DIAGNOSTICS. Pet Tumor Screening Service Product Portfolio
- 8.7.5 CANCAN DIAGNOSTICS. Recent Developments
- 8.8 IDEXX Laboratories
- 8.8.1 IDEXX Laboratories Company Information
- 8.8.2 IDEXX Laboratories Business Overview
- 8.8.3 IDEXX Laboratories Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.8.4 IDEXX Laboratories Pet Tumor Screening Service Product Portfolio
- 8.8.5 IDEXX Laboratories Recent Developments
- 8.9 Zoetis
- 8.9.1 Zoetis Company Information
- 8.9.2 Zoetis Business Overview
- 8.9.3 Zoetis Pet Tumor Screening Service Revenue and Gross Margin (2021-2026)
- 8.9.4 Zoetis Pet Tumor Screening Service Product Portfolio
- 8.9.5 Zoetis Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst